TrialInvestigational new drugs2018

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Paul Monk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.